InvestorsHub Logo
Followers 154
Posts 2653
Boards Moderated 0
Alias Born 01/29/2004

Re: nidan7500 post# 276057

Thursday, 10/15/2020 10:42:36 AM

Thursday, October 15, 2020 10:42:36 AM

Post# of 464084
For "them," not enough.

If you had to predict how this news will play out in academia, NIH, BP...what news-PR-pub-other, would you be looking for next???


External press accounts of the Anavex Parkinson's disease dementia clinical trial results will be have statements similar to this:

"Professor Dorglemeyer at Harvard stated, 'Although thought to be positive (no actual data were released), results from the Anavex clinical trial must be understood to be merely preliminary. The drug cannot be approved for use until further, replicated clinical trials are performed.'"

Now, if the study were run by a "real" pharmaceutical, such as Biogin, everything positive would have been in the headline: "New Drug Can Treat Parkinson's. Very Safe, Effective."

Biogin is headquartered in Cambridge, MA. Only smart people live and work there. "Anavex? Who ever heard of them?"
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News